Santarus, Inc. (NASDAQ: SNTS) today announced that Debra P. Crawford, senior vice president and chief financial officer, will make a presentation at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013, at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in New York City.
A webcast of the presentation will be available during the event at www.santarus.com and will be archived and available on the website for 14 days.
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZAÂ® (metformin hydrochloride extended release tablets) and CYCLOSETÂ® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on FENOGLIDEÂ® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol. In mid-February 2013, the company plans to begin promoting UCERISâ„˘ (budesonide) extended release tablets for the induction of remission of active, mild to moderate ulcerative colitis and ZEGERIDÂ® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. Full prescribing and safety information for Santarusâ€™ products are available at www.santarus.com.
Santarusâ€™ product development pipeline includes the investigational drug RUCONESTÂ® (recombinant human C1 esterase inhibitor) for treatment of acute attacks of hereditary angioedema. The company expects to submit a biologics license application (BLA) to the U.S. Food and Drug Administration for RUCONEST in the first half of 2013. Santarus is also developing rifamycin SV MMXÂ®, which is in Phase III clinical testing for treatment of travelersâ€™ diarrhea. In addition, enrollment has been completed in a Phase I clinical program with SAN-300, the companyâ€™s investigational monoclonal antibody. More information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarusâ€™ business, including, without limitation: difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarusâ€™ products; and other risks detailed in Santarusâ€™ prior press releases as well as in public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SantarusÂ®, FENOGLIDEÂ®, UCERISâ„˘ and ZEGERIDÂ® are trademarks of Santarus, Inc.GLUMETZAÂ® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc.CYCLOSETÂ® is a trademark of VeroScience LLC.MMXÂ® is a trademark of Cosmo Technologies Limited. RUCONESTÂ® is a trademark of Pharming Group N.V.Business Wire
Last updated on: 06/02/2013